智利政府发声：科兴疫苗让重症率下降83.7%，死亡率下降100%，广泛采用科兴疫苗是完全正确的决策

向问天 说:
On Sunday, Chilean science minister Andres Couve said it was important to focus on the data and the vaccine's effectiveness in reducing illness that required medical treatment or being hospitalized or dying, which it achieved in the Brazilian study in 83.7% and 100% of cases respectively.

点击展开...
这个新闻上说：
He said Chile’s health ministry will shortly publish a real world study on the effectiveness of both vaccines rolled out in its population and appealed to Chileans to continue to participate in the vaccination programme.
坐等。根据他的口气，应该差别不大，要不然他替中国疫苗辩护，结果出来肯定会被口水淹死。
 
billwanhua 说:
综合各大主流媒体报道，我对目前疫苗的有效性有以下总结，纯粹个人观点，非喜勿喷，欢迎讨论：
  1. 在预防感染有效性方面，mRNA疫苗甩其他各种疫苗几条街。 如果没有变异，疫苗充足，mRNA疫苗应该是最优选择。
  2. 目前没有确凿数据说明mRNA疫苗比其他各种疫苗对预防ICU或者预防死亡更有效。美国有报道，打了二针mRNA疫苗感染死亡的。其他很多疫苗三期实验都说100%防止死亡，但是实际情况不好说，肯定没有100%
  3. mRNA疫苗对于变异可能效果不大。打个简单比喻，mRNA疫苗针对特定突刺片段，就像治疗癌症的定向靶药，能够有的放矢，效果当然好，但是如果靶子变了，特别是其他片段，效果可想而知。目前多个研究都证明mRNA对南非变种效果不大。以色列实战降低8倍（https://www.forbes.com/sites/williamhaseltine/2021/04/11/the-pfizerbiontech-covid-19-vaccine-is-less-effective-against-the-south-african-and-uk-variants-than-against-the-original-virus-according-to-a-new-real-world-study-from-israel/?sh=2f14b8bd5888）牛津大学文章说7.6倍（https://www.ox.ac.uk/news/2021-03-18-existing-vaccines-may-protect-against-brazilian-coronavirus-variant）， Moderna自己的研究降低6倍（https://www.aljazeera.com/news/2021/4/11/what-we-know-about-the-south-african-coronavirus-variant）。 可笑的是辉瑞自己根据很少的cases研究得出的结论是对南非病毒100%有效(Trial: Pfizer COVID Vax Effective Against South African Variant).
  4. 目前不清楚灭活疫苗对于变种的有效性。巴西最近报道好像对P.1比较好（一针接近50%）
  5. 基本上，以后可能每年都需要打疫苗，目前当务之急是把各种疫苗成本降低到感冒疫苗的水平，要不然大部分国家都会破产。
点击展开...
全球仍有海量感染者，继续变异可能性较大，现有疫苗对未来变异效果如何，不好说。人类不大可能把新冠赶尽杀绝，希望未来能够把死亡率降至流感级别
 
春夏秋鼕 说:
全球仍有海量感染者，继续变异可能性较大，现有疫苗对未来变异效果如何，不好说。人类不大可能把新冠赶尽杀绝，希望未来能够把死亡率降至流感级别
点击展开...
是的，虽然新冠病毒比流感变异速度慢，但是基数太大（太多的感染者），变异超过想象。
 
thehill.com

Alarming new study shows South African variant can ‘break through’ Pfizer vaccine

Israeli researchers found in a study released Saturday that the COVID-19 mutation first discovered in South Africa has a greater likelihood of “breaking through” the Pfizer-BioNTech vaccine than ot…
thehill.com thehill.com


“Based on patterns in the general population, we would have expected just one case of the South African variant, but we saw eight,” Prof. Adi Stern, lead research in the group, told The Times of Israel. “Obviously, this result didn’t make me happy.”

“We can say it’s less effective, but more research is needed to establish exactly how much,” Stern said.

Pharmaceutical company Moderna’s Chief Medical Officer Tal Zaks said Wednesday that booster shots designed to protect against emerging variants should be ready by the end of 2021. The National Institute of Allergies and Infectious Diseases is working with the company.
为什么要等到年底？不是mRNA能很快就做出来
 
您必须登录或注册才可回复。
后退
顶部